menu
    • menu
    [{"orgOrder":0,"company":"Xeno Biosciences","sponsor":"LPOXY Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Sidiprev","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Xeno Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Oral Metered Dose Inhaler","sponsorNew":"Xeno Biosciences \/ LPOXY Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xeno Biosciences \/ LPOXY Therapeutics"},{"orgOrder":0,"company":"Xeno Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"XEN-101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Xeno Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xeno Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeno Biosciences \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Xeno Biosciences

    Menu

    Xeno Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xeno Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Xeno Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sidiprev

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : LPOXY Therapeutics

                            Deal Size : $7.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            LPOXY Therapeutics Acquires Assets from Xeno Biosciences for C. difficile Therapy

                            Details : LPOXY will acquire Xeno's intellectual property portfolio, and will use these assets to advance Sidiprev, a novel therapy aimed at preventing Clostridioides difficile infections.

                            Product Name : Sidiprev

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 03, 2025

                            Lead Product(s) : Sidiprev

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : LPOXY Therapeutics

                            Deal Size : $7.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xeno Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Xeno Biosciences

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XEN-101

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xeno Biosciences Starts Phase 1b Proof-of-Concept Study in Obesity

                            Details : XEN-101 is an oral investigational treatment for obesity, which works by mimicking the microbiota changes induced by gastric bypass surgery.

                            Product Name : XEN-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 25, 2024

                            Lead Product(s) : XEN-101

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth